newsfilter
← Latest News
Business Wire·

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Recently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC Enrollment ongoing for JANX007 and JANX008 Update on JANX007 and JANX008 data is anticipated in 2025 R&D Day is